Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Name:	us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Reductions in Research and Development Expense	$ 100	$ 0	$ 500	$ 0
Australia research and development refundable tax credit	1,042		1,042		$ 1,128
Novosteo
Restructuring Cost and Reserve [Line Items]
Australia research and development refundable tax credit	$ 600		$ 600